Acute Transaminitis: Assessment and Management
This mild hepatocellular transaminitis (AST 68, ALT 91) is most likely chemotherapy-related, specifically attributable to the recent Dara-CyBorD regimen, with bortezomib and cyclophosphamide being the primary culprits. Given the normal bilirubin (0.3 mg/dL) and only modest alkaline phosphatase elevation (119 U/L), this represents mild drug-induced liver injury (DILI) that does not yet meet criteria for holding chemotherapy 1.
Etiology Analysis
Pattern Recognition
The R-value calculation [(ALT/ULN)/(ALP/ULN)] yields approximately 4.5, confirming a hepatocellular injury pattern (R ≥5 approaches hepatocellular; R=4.5 is mixed-to-hepatocellular) 1. This pattern, combined with:
- Normal bilirubin
- Timing 2 weeks post-chemotherapy
- Absence of hypotension or shock
- No documented biliary obstruction on imaging
...strongly supports chemotherapy-induced hepatotoxicity over alternative diagnoses.
Specific Drug Contributions
Bortezomib is a well-documented hepatotoxin. The FDA label explicitly states that bortezomib exposure increases in patients with hepatic impairment, though no dose adjustment is required for mild impairment (bilirubin ≤1× ULN and AST > ULN) 2. Recent real-world data demonstrates that 33% of patients have baseline transaminase elevation, 40% at 1 month, and 24% at 3 months on bortezomib-based regimens, with predominantly cholestatic patterns (96%) developing de novo in 23.4% of patients within the first month 3.
Cyclophosphamide contributes additional hepatotoxic potential in this combination.
Daratumumab rarely causes hepatotoxicity. While one case report describes fulminant hepatic failure with daratumumab 4, this is exceedingly rare and the ANDROMEDA trial safety data showed no significant hepatotoxicity signal 5. Daratumumab pharmacokinetics are unaffected by mild-to-moderate hepatic impairment 6.
Critical Threshold Assessment
Current Status: Continue Chemotherapy
Your patient does NOT meet criteria for holding study drug per 2024 oncology DILI guidelines 1:
- ALT is 91 U/L (~2.3× ULN) — below the 3× ULN threshold
- Total bilirubin is 0.3 mg/dL — normal, well below the 2× ULN threshold
- The guideline states: "Study drug should be withheld if ALT ≥3× ULN AND TBIL ≥2× ULN, particularly if ALP ≤2× ULN"
Your patient meets NONE of these criteria for drug discontinuation.
Monitoring Thresholds
For patients with near-normal baseline ALT (which appears to be your patient's case given no prior values), hold chemotherapy if 1:
- ALT rises to ≥3× ULN (≥120 U/L) AND bilirubin ≥2× ULN (≥2.4 mg/dL)
- For isolated transaminitis without bilirubin elevation: evaluate alternative causes if ALT >5× ULN (>200 U/L)
Assessment
Mild drug-induced hepatocellular injury secondary to Dara-CyBorD chemotherapy, most likely bortezomib and cyclophosphamide-mediated. The injury pattern, timing, and absence of alternative high-risk features (hypotension, biliary obstruction, synthetic dysfunction) support this diagnosis. Importantly, liver injury at 3 months post-treatment independently predicts shorter overall survival (HR 2.83) in bortezomib-treated myeloma patients, making close monitoring essential 3.
Plan
Immediate Actions
- Continue current chemotherapy regimen — thresholds for holding not met 1
- Obtain PT/INR immediately to assess hepatic synthetic function (as you appropriately planned)
- Trend LFTs every 2-3 days (not daily unless worsening) — include AST, ALT, alkaline phosphatase, total bilirubin
Medication Management
- Comprehensive medication reconciliation:
- Eliminate all non-essential hepatotoxic agents
- Strictly avoid acetaminophen and acetaminophen-containing products
- Review all supplements, herbals, and over-the-counter medications
- Consider holding statins if prescribed
Diagnostic Workup (Tiered Approach per Guidelines 1)
Tier 1 — Obtain now:
- Hepatitis panel: HBsAg, anti-HBc (total), anti-HCV, HCV RNA
- Note: Anti-CD20 therapy can cause false-negative viral serology, but daratumumab (anti-CD38) does not have this limitation 1
- Hepatitis A IgM
- Autoimmune hepatitis serologies: ANA, anti-smooth muscle antibody, IgG level
- Right upper quadrant ultrasound with Doppler (to exclude biliary obstruction, hepatic vein thrombosis, infiltration)
Tier 2 — If Tier 1 negative and transaminases worsen:
- CMV PCR, EBV PCR
- Ceruloplasmin and 24-hour urine copper (Wilson's disease — less likely given age)
- Alpha-1 antitrypsin level and phenotype
- Consider MRCP if cholestatic pattern evolves 1
Coordination
- Notify Hematology/Oncology immediately with current LFT values and plan
- Establish clear escalation thresholds with oncology:
- Hold chemotherapy if ALT ≥3× ULN (≥120 U/L) with bilirubin ≥2× ULN
- Urgent hepatology consultation if ALT >5× ULN or any bilirubin elevation develops
- Discontinue chemotherapy permanently if no alternative cause identified and Hy's Law criteria develop (ALT ≥3× ULN + bilirubin ≥2× ULN + ALP <2× ULN)
Prognostic Consideration
Critical caveat: If transaminase abnormalities persist at 3 months, this independently predicts shorter overall survival (HR 2.83, p=0.011) in bortezomib-treated patients 3. This finding suggests that persistent liver injury reflects underlying disease biology rather than simple drug toxicity, warranting heightened surveillance for disease progression.
What NOT to Do
- Do not hold chemotherapy prematurely — current values do not meet thresholds and premature discontinuation risks undertreating myeloma
- Do not obtain liver biopsy at this stage — reserved for non-resolving or worsening injury after comprehensive workup 1
- Do not attribute this solely to "polypharmacy" without systematic medication review and viral/autoimmune exclusion
The hepatocellular pattern makes viral hepatitis and autoimmune hepatitis more likely differential diagnoses than biliary obstruction, but the temporal relationship to chemotherapy and absence of synthetic dysfunction strongly favor DILI 7.